Fjarde AP Fonden Fourth Swedish National Pension Fund Grows Stake in Veeva Systems Inc. $VEEV

Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its position in Veeva Systems Inc. (NYSE:VEEV) by 8.3% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 47,169 shares of the technology company’s stock after purchasing an additional 3,600 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Veeva Systems were worth $13,584,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. GAMMA Investing LLC boosted its position in Veeva Systems by 13.8% in the first quarter. GAMMA Investing LLC now owns 1,823 shares of the technology company’s stock worth $422,000 after purchasing an additional 221 shares during the last quarter. Spire Wealth Management boosted its holdings in shares of Veeva Systems by 37.1% in the first quarter. Spire Wealth Management now owns 277 shares of the technology company’s stock worth $64,000 after buying an additional 75 shares during the last quarter. Bessemer Group Inc. boosted its holdings in shares of Veeva Systems by 4.9% in the first quarter. Bessemer Group Inc. now owns 2,379 shares of the technology company’s stock worth $551,000 after buying an additional 111 shares during the last quarter. Golden State Wealth Management LLC boosted its holdings in shares of Veeva Systems by 152.9% in the first quarter. Golden State Wealth Management LLC now owns 129 shares of the technology company’s stock worth $30,000 after buying an additional 78 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Veeva Systems by 394.9% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,222 shares of the technology company’s stock worth $755,000 after buying an additional 2,571 shares during the last quarter. 88.20% of the stock is currently owned by hedge funds and other institutional investors.

Veeva Systems Stock Down 1.3%

Shares of Veeva Systems stock opened at $291.95 on Wednesday. The stock’s 50-day simple moving average is $285.11 and its 200-day simple moving average is $271.15. Veeva Systems Inc. has a 52 week low of $201.54 and a 52 week high of $310.50. The company has a market capitalization of $47.85 billion, a price-to-earnings ratio of 59.95, a PEG ratio of 2.29 and a beta of 0.98.

Veeva Systems (NYSE:VEEV) last posted its quarterly earnings results on Wednesday, August 27th. The technology company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.90 by ($0.64). Veeva Systems had a return on equity of 13.72% and a net margin of 27.29%.The business had revenue of $789.08 million during the quarter, compared to analysts’ expectations of $768.49 million. During the same period in the prior year, the firm posted $1.62 earnings per share. The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. Veeva Systems has set its Q3 2026 guidance at 1.940-1.950 EPS. FY 2026 guidance at 7.780-7.780 EPS. On average, equities analysts expect that Veeva Systems Inc. will post 4.35 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on VEEV shares. Wall Street Zen raised shares of Veeva Systems from a “hold” rating to a “buy” rating in a report on Saturday, October 11th. William Blair reiterated an “outperform” rating on shares of Veeva Systems in a research note on Friday, October 17th. Canaccord Genuity Group lifted their target price on Veeva Systems from $270.00 to $300.00 and gave the company a “hold” rating in a research report on Thursday, August 28th. BTIG Research reiterated a “buy” rating and set a $340.00 target price on shares of Veeva Systems in a research report on Friday, October 17th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $355.00 target price on shares of Veeva Systems in a research report on Friday, October 17th. Seventeen equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Veeva Systems presently has an average rating of “Moderate Buy” and a consensus price target of $307.58.

Insider Transactions at Veeva Systems

In other Veeva Systems news, insider Thomas D. Schwenger sold 3,350 shares of the business’s stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $300.04, for a total value of $1,005,134.00. Following the sale, the insider owned 23,773 shares in the company, valued at $7,132,850.92. The trade was a 12.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jonathan Faddis sold 14,595 shares of the business’s stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $300.00, for a total transaction of $4,378,500.00. Following the completion of the sale, the senior vice president owned 8,588 shares in the company, valued at approximately $2,576,400. The trade was a 62.96% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 24,665 shares of company stock valued at $7,438,000. 10.30% of the stock is currently owned by corporate insiders.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.